share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中進醫療 | 6-K:外國發行人報告

美股SEC公告 ·  02/06 05:08

牛牛AI助理已提取核心訊息

Jin Medical International Ltd. has announced the completion of a share subdivision following shareholder approval at an extraordinary general meeting on January 30, 2024. The subdivision, effective February 8, 2024, will see each existing ordinary share with a par value of US$0.001 divided into twenty new ordinary shares with a par value of US$0.00005 each. This change increases the total number of authorized shares to 1,000,000,000 with the adjusted par value. Shareholders will not receive fractional shares but can contact the transfer agent, Transhare Corporation, for instructions on exchanging their share certificates to reflect the subdivision. The announcement was made in compliance with the SEC regulations and signed by CEO Erqi Wang on February 5, 2024.
Jin Medical International Ltd. has announced the completion of a share subdivision following shareholder approval at an extraordinary general meeting on January 30, 2024. The subdivision, effective February 8, 2024, will see each existing ordinary share with a par value of US$0.001 divided into twenty new ordinary shares with a par value of US$0.00005 each. This change increases the total number of authorized shares to 1,000,000,000 with the adjusted par value. Shareholders will not receive fractional shares but can contact the transfer agent, Transhare Corporation, for instructions on exchanging their share certificates to reflect the subdivision. The announcement was made in compliance with the SEC regulations and signed by CEO Erqi Wang on February 5, 2024.
在2024年1月30日的股東特別大會上獲得股東批准後,金醫療國際有限公司宣佈完成股份拆分。該細分自2024年2月8日起生效,將把每股面值爲0.001美元的現有普通股分成二十股新普通股,每股面值爲0.00005美元。調整後的面值後,這一變更將授權股票的總數增加到1,000,000,000。股東不會獲得部分股份,但可以聯繫過戶代理人Transhare Corporation,以獲取有關交換股票證書以反映細分的說明。該公告是根據美國證券交易委員會的規定發佈的,由首席執行官王爾奇於2024年2月5日簽署。
在2024年1月30日的股東特別大會上獲得股東批准後,金醫療國際有限公司宣佈完成股份拆分。該細分自2024年2月8日起生效,將把每股面值爲0.001美元的現有普通股分成二十股新普通股,每股面值爲0.00005美元。調整後的面值後,這一變更將授權股票的總數增加到1,000,000,000。股東不會獲得部分股份,但可以聯繫過戶代理人Transhare Corporation,以獲取有關交換股票證書以反映細分的說明。該公告是根據美國證券交易委員會的規定發佈的,由首席執行官王爾奇於2024年2月5日簽署。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。